Put Options

16 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$64.76 - $79.84 $27.9 Million - $34.4 Million
-430,900 Reduced 87.78%
60,000 $4.11 Million
Q1 2024

May 15, 2024

BUY
$64.37 - $75.65 $29.7 Million - $34.9 Million
460,900 Added 1536.33%
490,900 $34 Million
Q4 2023

Feb 14, 2024

SELL
$46.37 - $73.65 $1.16 Million - $1.84 Million
-25,000 Reduced 45.45%
30,000 $2.15 Million
Q3 2023

Nov 14, 2023

BUY
$52.09 - $64.1 $2.08 Million - $2.56 Million
40,000 Added 266.67%
55,000 $2.86 Million
Q2 2023

Aug 14, 2023

SELL
$54.67 - $66.44 $820,050 - $996,600
-15,000 Reduced 50.0%
15,000 $949,000
Q1 2023

May 15, 2023

BUY
$43.8 - $56.99 $565,020 - $735,171
12,900 Added 75.44%
30,000 $1.62 Million
Q3 2022

Nov 14, 2022

SELL
$42.7 - $59.99 $2.56 Million - $3.6 Million
-60,000 Reduced 77.82%
17,100 $796,000
Q2 2022

Aug 15, 2022

BUY
$43.0 - $65.64 $3.32 Million - $5.06 Million
77,100 New
77,100 $4.4 Million
Q1 2022

May 13, 2022

SELL
$38.74 - $62.09 $7.25 Million - $11.6 Million
-187,200 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$35.2 - $53.42 $5.37 Million - $8.15 Million
152,500 Added 439.48%
187,200 $9.8 Million
Q1 2021

May 17, 2021

SELL
$30.8 - $39.51 $8.84 Million - $11.3 Million
-287,100 Reduced 89.22%
34,700 $1.18 Million
Q2 2020

Aug 14, 2020

SELL
$14.35 - $26.64 $15.4 Million - $28.5 Million
-1,071,200 Reduced 76.9%
321,800 $8.26 Million
Q4 2019

Feb 13, 2020

BUY
$7.26 - $38.49 $6.2 Million - $32.9 Million
854,000 Added 158.44%
1,393,000 $47.8 Million
Q3 2019

Nov 14, 2019

BUY
$7.47 - $14.03 $3.26 Million - $6.13 Million
436,700 Added 426.88%
539,000 $4.03 Million
Q2 2019

Aug 13, 2019

BUY
$10.65 - $14.29 $663,495 - $890,267
62,300 Added 155.75%
102,300 $1.33 Million
Q1 2019

May 14, 2019

BUY
$10.9 - $14.09 $436,000 - $563,600
40,000 New
40,000 $488,000

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $7.86B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.